Literature DB >> 10716770

Type IV collagen and its degradation in paralyzed human muscle: effect of functional electrical stimulation.

S O Koskinen1, M Kjaer, T Mohr, F B Sørensen, T Suuronen, T E Takala.   

Abstract

The purpose of this study was to evaluate the effects of spinal cord injury (SCI) and functional electrical stimulation (FES) of paralyzed muscles on type IV collagen content and proteins involving its degradation, which is initiated by matrix metalloproteinase (MMP)-2 and -9 and regulated by their tissue inhibitors (TIMPs)-2 and -1. Ten SCI subjects participated in an 18-month program of functional electrical stimulation (FES) of their leg muscles. Needle biopsies were taken from the vastus lateralis muscle before and at various times during the training period, and from able-bodied controls. Type IV collagen concentration was unaltered. ProMMP-2 level of SCI subjects before the training period tended to be higher than able-bodied controls and was significantly above the control level after FES. MMP-9 concentration was unchanged. The results suggest accelerated type IV collagen turnover in skeletal muscle of SCI individuals especially after FES as a part of adaptive process of the muscle. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716770     DOI: 10.1002/(sici)1097-4598(200004)23:4<580::aid-mus18>3.0.co;2-4

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

1.  Why exercise in paraplegia?

Authors:  M Kjaer
Journal:  Br J Sports Med       Date:  2000-10       Impact factor: 13.800

2.  Magnetic resonance technology in training and sports.

Authors:  T B Price
Journal:  Br J Sports Med       Date:  2000-10       Impact factor: 13.800

3.  Training-induced changes in peritendinous type I collagen turnover determined by microdialysis in humans.

Authors:  H Langberg; L Rosendal; M Kjaer
Journal:  J Physiol       Date:  2001-07-01       Impact factor: 5.182

4.  Muscle expression of genes associated with inflammation, growth, and remodeling is strongly correlated in older adults with resistance training outcomes.

Authors:  Richard A Dennis; Haiyan Zhu; Patrick M Kortebein; Heather M Bush; Jonathan F Harvey; Dennis H Sullivan; Charlotte A Peterson
Journal:  Physiol Genomics       Date:  2009-05-12       Impact factor: 3.107

5.  Matrix metalloprotease-3 and tissue inhibitor of metalloprotease-1 mRNA and protein levels are altered in response to traumatic skeletal muscle injury.

Authors:  Maria L Urso; Eric R Szelenyi; Gordon L Warren; Brian R Barnes
Journal:  Eur J Appl Physiol       Date:  2010-03-27       Impact factor: 3.078

6.  Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice.

Authors:  Saurabh Dahiya; Shephali Bhatnagar; Sajedah M Hindi; Chunhui Jiang; Pradyut K Paul; Shihuan Kuang; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2011-08-16       Impact factor: 6.150

7.  Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.

Authors:  Hong Li; Ashwani Mittal; Denys Y Makonchuk; Shephali Bhatnagar; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2009-04-28       Impact factor: 6.150

Review 8.  Wasting mechanisms in muscular dystrophy.

Authors:  Jonghyun Shin; Marjan M Tajrishi; Yuji Ogura; Ashok Kumar
Journal:  Int J Biochem Cell Biol       Date:  2013-05-11       Impact factor: 5.085

9.  Lack of type XV collagen causes a skeletal myopathy and cardiovascular defects in mice.

Authors:  L Eklund; J Piuhola; J Komulainen; R Sormunen; C Ongvarrasopone; R Fássler; A Muona; M Ilves; H Ruskoaho; T E Takala; T Pihlajaniemi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

Review 10.  Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy.

Authors:  Yuji Ogura; Marjan M Tajrishi; Shuichi Sato; Sajedah M Hindi; Ashok Kumar
Journal:  Front Cell Dev Biol       Date:  2014-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.